TriangleNCT00109928 · OUTCOME
Response Rate
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- up to 3 years or time of disease progression
What was measured
Complete Response(CR) is a complete disappearance of all disease with the exception of nodes. No new lesions. previously enlarged organs must have regressed and not be palpable. Bone marrow(BM) must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRU) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM. Partial Response(PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes.
Analysis population: All eligible patients who started protocol treatment were included in the analysis.
Groups in this outcome
PEGS
Patients received IV cisplatin 25 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4, gemcitabine 1000 mg/m2 day 1 and solumedrol 250 mg days 1-4 of a 21 day cycle for 6 cycles.
| Group | Source count |
|---|---|
| PEGS | 33 |
Reported measurements
Complete Response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| PEGS | 6 | Not reported | Not reported | Not reported | Not reported |
Unconfirmed Complete Response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| PEGS | 2 | Not reported | Not reported | Not reported | Not reported |
Partial Response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| PEGS | 5 | Not reported | Not reported | Not reported | Not reported |
No Response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| PEGS | 20 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 6
- title
- Complete Response
- categories
- measurements
- group Id
- OG000
- value
- 2
- title
- Unconfirmed Complete Response
- categories
- measurements
- group Id
- OG000
- value
- 5
- title
- Partial Response
- categories
- measurements
- group Id
- OG000
- value
- 20
- title
- No Response
- denoms
- counts
- group Id
- OG000
- value
- 33
- units
- Participants
- description
- Complete Response(CR) is a complete disappearance of all disease with the exception of nodes. No new lesions. previously enlarged organs must have regressed and not be palpable. Bone marrow(BM) must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRU) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM. Partial Response(PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes.
- groups
- description
- Patients received IV cisplatin 25 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4, gemcitabine 1000 mg/m2 day 1 and solumedrol 250 mg days 1-4 of a 21 day cycle for 6 cycles.
- id
- OG000
- title
- PEGS
- param Type
- NUMBER
- population Description
- All eligible patients who started protocol treatment were included in the analysis.
- time Frame
- up to 3 years or time of disease progression
- title
- Response Rate
- type
- SECONDARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice